Evaluation of the delivery of an anti-Listeria endolysin via CRISPR-Cas9 engineered probiotic Saccharomyces boulardii.
- 2026-02-26
- Applied microbiology and biotechnology 110(1)
- David Sáez Moreno
- João Paulo Carvalho
- Ellen Murray
- Natalia Soledad Ríos Colombo
- Alexandre Lamas
- Alejandra Cardelle Cobas
- Colin Hill
- Joana Azeredo
- Lucília Domingues
- PubMed: 41748831
- DOI: 10.1007/s00253-026-13749-6
- Low evidence
the anti-Listeria effect was reduced potentially due to the lower metabolic activity of S. boulardii and the higher competition with the intestinal microbiome
- Effect
- Harmful
- Effect size
- Small